APRE

Aprea Therapeutics Inc Cross-source read$0.79 1.49%
Health CareCUSIP 03836J201· EOD Sep 4, 2026

Among active 13F managers last quarter, 3 opened and 1 reduced; the largest holder to move was Citadel Advisors LLC (new position). No open-market insider trades in the last 180 days.

Tracked 13F holders
25
6 in Q2 2026 filings
13F value (tracked)
$1.8M
Smart-money readBullish
Net sellingNet buying
Funds · active managers, latest 13F
3 adding · 1 trimming
Insiders · Form 4 open-market, 180d
0 buying · 0 selling
US House · STOCK Act, 180d
0 buying · 0 selling

Funds lean in and no leg opposes.

Price & smart-money activity

$0.79 1.49%5Y -99.1%
$0.55$29.94$59.32$88.71$118.10202120222023202420252026622222224229222234263
Hover for who · click for detailEnd-of-day closing prices52w $0.59 – $1.65

Who owns APRE?

25 tracked 13F filers · ranked by shares held

25 tracked 13F filers disclose a position in APRE as of the latest SEC 13F filings, a combined $1.8M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.

#FundSharesPosition valueLast moveAs ofHistory
1AIGH Capital Management LLC1.0M
$815K
Held
Q2 2026
2Vestal Point Capital, LP350K
$281K
Held
Q2 2026
3Sphera Funds Management LTD.270K
$217K
Held
Q2 2026
4Nantahala Capital Management, LLC206K
$165K
Held
Q2 2026
5Geode Capital Management, LLC75K
$60K
−37%
Reduced · −44K sh
Q2 2026
6Citadel Advisors LLC59K
$47K
New
+59K sh
Q2 2026
7Diadema Partners LP45K
$36K
New
+45K sh
Q2 2026
8BNP Paribas Financial Markets40K
$30K
+46%
Added · +12K sh
Q1 2026
9Vanguard Fiduciary Trust Co38K
$31K
Held
Q2 2026
10Renaissance Technologies LLC25K
$19K
New
+25K sh
Q1 2026
11Vanguard Capital Management LLC23K
$18K
+17%
Added · +3K sh
Q2 2026
12Morgan Stanley22K
$17K
−71%
Reduced · −55K sh
Q1 2026
13LPL Financial LLC21K
$16K
−19%
Reduced · −5K sh
Q1 2026
14HighTower Advisors, LLC14K
$11K
Held
Q1 2026
15Susquehanna International Group, LLP13K
$10K
New
+13K sh
Q1 2026
16Persistent Asset Partners Ltd11K
$9K
New
+11K sh
Q2 2026
17BlackRock, Inc.7K
$6K
−16%
Reduced · −1K sh
Q2 2026
18Tower Research Capital LLC (TRC)5K
$4K
−34%
Reduced · −3K sh
Q1 2026
19UBS Group AG2K
$2K
−13%
Reduced · −308 sh
Q1 2026
20Group One Trading LLC577
$463
Held
Q2 2026
21Osaic Holdings, Inc.295
$225
−1.7%
Reduced · −5 sh
Q1 2026
22WealthCollab, LLC158
$127
Held
Q2 2026
23Integrated Wealth Concepts LLC46
$36
New
+46 sh
Q2 2026
24FMR LLC45
$36
New
+45 sh
Q2 2026
25SBI Securities Co., Ltd.16
$13
Held
Q2 2026

Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.

Is APRE being bought or sold by institutions?

Last quarter, 3 funds opened a new position in APRE, while 1 reduced. Based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).

Opened
3
funds took a first position
Reduced
1
reduced, still holding
Biggest moves · ranked by size of the change, positions above a floor

Funds that own APRE also own

CompanyCo-held byTheir position there
Novo-Nordisk A/s-Spons ADRNVO7 funds$133.4M
Bristol-Myers Squibb CoBMY7 funds$124.0M
Cogent Biosciences IncCOGT7 funds$96.9M
Dyne Therapeutics IncDYN7 funds$85.6M
Cellebrite Di LtdCLBT7 funds$48.3M
Verastem IncVSTM7 funds$23.1M
United Therapeutics CorpUTHR6 funds$1.1B
Sandisk CorpSNDK6 funds$896.2M
Neurocrine Biosciences IncNBIX6 funds$484.0M
Intel CorpINTC6 funds$475.3M
Unitedhealth Group IncUNH6 funds$327.7M
Biomarin Pharmaceutical IncBMRN6 funds$272.8M

Ranked by how many of APRE's tracked holders also hold each name. The last column is those co-holders' combined reported position in that name, not in APRE.

Insider activity (Form 4)

Full insider page →
Net · 180d
$0
0 open-market transactions
DateInsiderRoleActionSharesValue
Jan 30, 2026Hamill John P.SrVP/CFO/Prin Fin & Acct OfcrBuy (P)6K$5K
Jan 30, 2026Gilad OrenPresident/CEO, DirectorBuy (P)28K$25K
Dec 10, 2025Hamill John P.SrVP/CFO/Prin Fin & Acct OfcrBuy (P)5K$6K
Dec 10, 2025Duey MarcDirectorBuy (P)21K$25K
Apr 3, 2025Gilad OrenPresident/CEO, DirectorBuy (P)
2 lots, same day
6K$10K
Oct 23, 2024Gilad OrenPresident/CEO, DirectorBuy (P)500$2K
Oct 18, 2024Duey MarcDirectorSell (S)6K$30K
Oct 16, 2024Duey MarcDirectorBuy (P)30K$132K
Oct 15, 2024Gilad OrenPresident/CEO, DirectorBuy (P)250$725
Oct 14, 2024Gilad OrenPresident/CEO, DirectorBuy (P)1K$3K
Oct 14, 2024Duey MarcDirectorBuy (P)190$490
Oct 11, 2024Seizinger Bernd R.DirectorBuy (P)10K$27K

One row per insider, day and transaction code; shares and value are summed across the lots. Every lot is on the full insider page and in the filing.

Do institutions, insiders and Congress agree?

Mixed signals

Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.

SEC EDGAR 13F + Form 4 + US House STOCK Act{ }get_ticker_confluence · API & MCP

Signals by source

Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive

SourceBuyingSellingNet
13F funds
Top 100 holders by value, passive included; the hero counts active managers only
27
Insiders
Form 4 open-market
00$0
US House
STOCK Act trades
00$0
Sector rotation
APRE is in Health Care, which smart money is rotating OUT OF
$6.6B

Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.

Institutional ownership over time

6 tracked filers in Q2 2026 filingsstill filing
01122Q3 2024Q1 2025Q3 2025Q1 2026Q2 2026
tracked filers holding their reported valueQ2 2026 filings so far: $884K
Each bar counts tracked filers with a position in that quarter's filings, so the newest bar excludes filers still on an earlier quarter. Arkolith's tracked universe has grown over this window; part of any long-run rise is coverage, not new buyers.

Recent filings

15 most recent

Keep exploring

Connected entities for APRE

Browse more

Build

Ask your agent what changed in APRE

This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/stocks/APRE/capital-change-brief"
Ask your agent
Use Arkolith's capital_change_brief for APRE.
Tell me what changed, whether insider activity
corroborates it, and cite the SEC evidence.

13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for APRE. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.